243 related articles for article (PubMed ID: 22541929)
1. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease.
Okanobo A; Chauhan SK; Dastjerdi MH; Kodati S; Dana R
Am J Ophthalmol; 2012 Jul; 154(1):63-71. PubMed ID: 22541929
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2.
Goyal S; Chauhan SK; Zhang Q; Dana R
Arch Ophthalmol; 2009 Jul; 127(7):882-7. PubMed ID: 19597109
[TBL] [Abstract][Full Text] [Related]
3. Topical omega-3 and omega-6 fatty acids for treatment of dry eye.
Rashid S; Jin Y; Ecoiffier T; Barabino S; Schaumberg DA; Dana MR
Arch Ophthalmol; 2008 Feb; 126(2):219-25. PubMed ID: 18268213
[TBL] [Abstract][Full Text] [Related]
4. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
[TBL] [Abstract][Full Text] [Related]
5. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Stevenson W; Sadrai Z; Hua J; Kodati S; Huang JF; Chauhan SK; Dana R
Cornea; 2014 Feb; 33(2):177-83. PubMed ID: 24342887
[TBL] [Abstract][Full Text] [Related]
6. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease.
Goyal S; Chauhan SK; Dana R
Arch Ophthalmol; 2012 Jan; 130(1):84-9. PubMed ID: 21911653
[TBL] [Abstract][Full Text] [Related]
7. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye.
Lee HS; Chauhan SK; Okanobo A; Nallasamy N; Dana R
Cornea; 2011 Dec; 30(12):1465-72. PubMed ID: 21993466
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
[TBL] [Abstract][Full Text] [Related]
10. Effects of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye.
Li Z; Choi JH; Oh HJ; Park SH; Lee JB; Yoon KC
Curr Eye Res; 2014 Sep; 39(9):871-8. PubMed ID: 24559509
[TBL] [Abstract][Full Text] [Related]
11. What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?
Amparo F; Jin Y; Hamrah P; Schaumberg DA; Dana R
Am J Ophthalmol; 2014 Jan; 157(1):69-77.e2. PubMed ID: 24060433
[TBL] [Abstract][Full Text] [Related]
12. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.
Vijmasi T; Chen FY; Chen YT; Gallup M; McNamara N
Mol Vis; 2013; 19():1957-65. PubMed ID: 24068863
[TBL] [Abstract][Full Text] [Related]
13. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.
Sadrai Z; Stevenson W; Okanobo A; Chen Y; Dohlman TH; Hua J; Amparo F; Chauhan SK; Dana R
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3584-91. PubMed ID: 22577075
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
16. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
Gehlsen U; Braun T; Notara M; Krösser S; Steven P
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye.
De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME; Pflugfelder SC
Exp Eye Res; 2006 Sep; 83(3):526-35. PubMed ID: 16643899
[TBL] [Abstract][Full Text] [Related]
19. Effect of Topical 5-Aminoimidazole-4-carboxamide-1-β-d-Ribofuranoside in a Mouse Model of Experimental Dry Eye.
Sung MS; Li Z; Cui L; Choi JS; Choi W; Park MJ; Park SH; Yoon KC
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3149-58. PubMed ID: 26024098
[TBL] [Abstract][Full Text] [Related]
20. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease.
Ecoiffier T; El Annan J; Rashid S; Schaumberg D; Dana R
Arch Ophthalmol; 2008 Dec; 126(12):1695-9. PubMed ID: 19064851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
